ClinicalTrials.gg
RecruitingNCT07502768EpiRev-NKTUpdated Jun 18, 2026

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

A Phase 1/2 interventional study of Tislelizumab and Zeprumetostat in Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma and Relapsed or Refractory NK/T-Cell Lymphoma, sponsored by Rong Tao. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Rong Tao · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China — 22 open to participants now, 25 under way, 2 of them phase 3. Lymphoma, Extranodal NK-T-Cell · China.

Planned enrollment
7th of 65
107 · median 40
Started
2026
with 7 others
Phase 1/2
7 of 73
2 open now
Primary completion
2027-12
later than 13 of 24 live
Registered
65th of 73
by date
Lead sponsor
4 of 73
Rong Tao

Among the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, this one is the 7th largest by planned enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2026, is one of 7 in phase 1/2, reaches primary completion later than 13 of the 24 other live ones, and was the 65th registered.

Lymphoma, Extranodal NK-T-Cell

270 studies on the registry are indexed under Lymphoma, Extranodal NK-T-Cell; 36 are open to participants now.

Browse Lymphoma, Extranodal NK-T-Cell studies →

Open to participants now

22 of the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Lymphoma, Extranodal NK-T-Cell studies recruiting now, 11 (55%) set no upper age limit and 8 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy. In phase Ib, two fixed dose levels of zeprumetostat in combination with tislelizumab will be evaluated to determine the recommended phase II dose (RP2D). In phase II, patients will be enrolled into 2 predefined cohorts according to prior exposure to PD-1 inhibitors to further evaluate efficacy and safety. The primary phase II endpoint is objective response rate at week 12 assessed by independent blinded imaging review according to Lugano 2014 criteria.

Read the detailed description

This is a multicenter, open-label, phase Ib/II clinical trial in relapsed or refractory NK/T-cell lymphoma.

In phase Ib, patients with relapsed or refractory NK/T-cell lymphoma after at least 1 prior asparaginase-based chemotherapy-containing regimen will receive tislelizumab 200 mg intravenously every 3 weeks in combination with zeprumetostat at 1 of 2 dose levels: 300 mg orally twice daily or 350 mg orally twice daily. The dose-limiting toxicity observation window is 21 days. If neither dose level is excessively toxic, enrollment will continue until 12 evaluable patients are included in each arm. Dose selection for phase II will be based on dose-limiting toxicity and objective response rate at week 12 assessed by independent blinded imaging review according to Lugano 2014 criteria. If efficacy is similar, the lower dose level will be preferred.

In phase II, patients will receive zeprumetostat at the RP2D plus tislelizumab 200 mg intravenously every 3 weeks. Patients will be enrolled into 2 predefined cohorts according to prior exposure to PD-1 inhibitors: Cohort-R (prior PD-1 exposed/refractory) and Cohort-N (PD-1 inhibitor-naive). Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, or study termination.

The primary phase II endpoint is objective response rate at week 12 assessed by independent blinded imaging review according to Lugano 2014 criteria. Secondary endpoints include complete response rate, duration of response, progression-free survival, overall survival, and safety. Exploratory endpoints include the association of ctDNA and EBV-DNA dynamics, PD-L1, EZH2/H3K27me3, and tumor microenvironment biomarkers with clinical outcome.

03

Conditions studied

  • Extranodal NK/T-cell Lymphoma
  • NK/T-cell Lymphoma
  • Relapsed or Refractory NK/T-Cell Lymphoma

Keywords

  • Tislelizumab
  • Zeprumetostat
  • EZH2 inhibitor
  • PD-1 inhibitor
  • NKTCL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • confirmed NK/T-cell lymphoma.
  • disease after at least 1 prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy.
  • At least 1 measurable or evaluable lesion according to Lugano 2014 criteria.
  • performance status 0 to 2.
  • greater than 12 weeks.
  • Adequate hematologic, hepatic, renal, coagulation, and cardiac function.
  • Recovery from prior anti-cancer treatment-related toxicities to grade 1 or baseline, except for specified stable irreversible toxicities allowed by the investigator.
  • Negative pregnancy test for women of .
  • Willingness to use effective .
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any EZH1/2 or EZH2 inhibitor.
  • hematopoietic stem cell transplantation within 5 years before study treatment.
  • Autologous hematopoietic stem cell transplantation within 3 months before study treatment.
  • Requirement for high-dose systemic or other therapy within 14 days before study treatment, except permitted local/inhaled or short-course use.
  • Cytotoxic chemotherapy not discontinued within 14 days before study treatment.
  • Systemic anti-cancer therapy or therapy within 4 weeks before study treatment.
  • Major surgery within 4 weeks or radiotherapy within 90 days before study treatment.
  • Active infection, including active/latent tuberculosis, infection, active or C with detectable viral nucleic acid, or other active viral infection.
  • Uncontrolled cardiovascular disease.
  • Persistent unresolved toxicities greater than grade 1 from prior therapy, except alopecia.
  • Gastrointestinal disorders or prior intestinal surgery that may impair oral drug absorption.
  • Pregnancy or breastfeeding.
  • Psychiatric illness or inability to provide .
  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (estimated)

Study arms

  • Experimental
    Phase Ib Dose Level A

    Tislelizumab 200 mg IV every 3 weeks plus zeprumetostat 300 mg orally twice daily.

    Drug: Tislelizumab · Drug: Zeprumetostat

  • Experimental
    Phase Ib Dose Level B

    Tislelizumab 200 mg IV every 3 weeks plus zeprumetostat 350 mg orally twice daily.

    Drug: Tislelizumab · Drug: Zeprumetostat

  • Experimental
    Phase II Cohort-R (Prior PD-1 Exposed/Refractory)

    Tislelizumab 200 mg IV every 3 weeks plus zeprumetostat at the RP2D in patients previously exposed or refractory to PD-1 inhibitor therapy.

    Drug: Tislelizumab · Drug: Zeprumetostat

  • Experimental
    Phase II Cohort-N (PD-1 Inhibitor-Naive)

    Tislelizumab 200 mg IV every 3 weeks plus zeprumetostat at the RP2D in patients without prior PD-1 inhibitor therapy.

    Drug: Tislelizumab · Drug: Zeprumetostat

Interventions

  • Tislelizumab 200 mg administered intravenously on day 1 of each 21-day cycle.

  • Zeprumetostat (SHR2554), an oral EZH2 inhibitor, administered twice daily. In phase Ib, dose levels are 300 mg BID and 350 mg BID. In phase II, zeprumetostat is administered at the recommended phase II dose selected from phase Ib.

06

What researchers measure

Primary outcomes

  1. Recommended Phase II Dose (RP2D) of zeprumetostat in combination with tislelizumab

    Determination of the recommended phase II dose based on dose-limiting toxicities during the first 21 days and objective response rate at week 12.

    Time frame: During phase Ib, up to 12 weeks

  2. Objective Response Rate (ORR) at Week 12

    Objective response rate assessed by independent blinded imaging review according to Lugano 2014 criteria during phase II.

    Time frame: Week 12

Secondary outcomes

  1. Complete Response Rate (CRR)

    Proportion of participants whose best overall response is complete response (CR) at week 12, as assessed according to Lugano 2014 criteria.

    Time frame: 12 weeks

  2. Duration of Response (DOR)

    Duration of response is defined as the time from first documented complete response (CR) or partial response (PR) to disease progression, relapse, or death, according to Lugano 2014 criteria.

    Time frame: From first documented CR or PR until first documented disease progression, relapse, or death, up to 36 months

  3. Progression-Free Survival (PFS)

    Progression-free survival is defined as the time from study enrollment/first dose to the first documentation of progressive disease or death from any cause, whichever occurs first.

    Time frame: From first dose until first documented disease progression or death from any cause, up to 36 months

  4. Overall Survival (OS)

    Overall survival is defined as the time from study enrollment/first dose to death from any cause.

    Time frame: From first dose until death from any cause, up to 36 months

  5. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs)

    Safety will be assessed by the incidence, type, severity, timing, seriousness, attribution, actions taken, and outcomes of adverse events, serious adverse events, and immune-related adverse events.

    Time frame: From signing of informed consent through 28 days after the last dose of study treatment

Other outcomes

  1. Objective Response Rate (ORR) in Predefined Biomarker Subgroups

    Objective response rate at week 12, assessed according to Lugano 2014 criteria, in predefined biomarker subgroups including PD-L1, EZH2/H3K27me3, EBV-DNA, ctDNA clearance, and other prospectively defined biomarker categories.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Song Y, Liu Y, Li ZM, Li L, Su H, Jin Z, Zuo X, Wu J, Zhou H, Li K, He C, Zhou J, Qi J, Hao S, Cai Z, Li Y, Wang W, Zhang X, Zou J, Zhu J. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol. 2022 Jul;9(7):e493-e503. doi: 10.1016/S2352-3026(22)00134-X. PubMed 35772429 ↗
  • Song Y, Jin Z, Li ZM, Liu Y, Li L, He C, Su H, Zhou H, Li K, Hao S, Zuo X, Wu J, Li D, Wu M, Sun X, Qi J, Cai Z, Li Z, Li Y, Huang Y, Shen J, Xiao Z, Zhu J. Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study. Clin Cancer Res. 2024 Apr 1;30(7):1248-1255. doi: 10.1158/1078-0432.CCR-23-2582. PubMed 38190117 ↗
  • Huang H, Tao R, Hao S, Yang Y, Cen H, Zhou H, Guo Y, Zou L, Cao J, Huang Y, Jin J, Zhang L, Yang H, Xing X, Zhang H, Liu Y, Ding K, Qi Q, Zhu X, Zhu D, Wang S, Fang T, Dai H, Shi Q, Yang J. Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study. J Clin Oncol. 2023 Jun 1;41(16):3032-3041. doi: 10.1200/JCO.22.02367. Epub 2023 Mar 30. PubMed 36996373 ↗
  • Tao R, Fan L, Song Y, Hu Y, Zhang W, Wang Y, Xu W, Li J. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther. 2021 Oct 27;6(1):365. doi: 10.1038/s41392-021-00768-0. PubMed 34702811 ↗

Individual participant data

Plan to share: Undecided — IPD sharing is currently undecided. The study team will determine whether de-identified participant-level data can be shared after study completion in accordance with institutional policy, participant consent, and applicable regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 31, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2028
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07502768
Lead sponsor
Rong Tao
Collaborators
Fudan University
Responsible party
Rong Tao (MD, Fudan University) — Sponsor-investigator
First posted
Mar 31, 2026
Start date
Apr 30, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Jun 18, 2026

Study contacts

Rong Tao, MD & PhD
Contact
hkutao@hotmail.com
008621-64175590 ext. 660103
Chuanxu Liu, MD & PhD
Contact
liuchaunxu@shca.or.cn
008621-64175590 ext. 660103
Rong Tao, MD & PhD
study chair · Shanghai Cancer Center
Chuanxu Liu, MD & PhD
principal investigator · Shanghai Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion